Model-based approaches to predict drug–drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond

Bibliography

• Giacomini KM, Huang SM, Tweedie DJ, Membrane transporters in drug development. Nat Rev Drug Discov 2010;9:215-36
   PubMed Web of Science ®Google Scholar
• Elsby R, Hilgendorf C, Fenner K. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1. Clin Pharmacol Ther 2012;92:584-98
   PubMed Web of Science ®Google Scholar
• Lai Y, Varma M, Feng B, Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development. Expert Opin Drug Metab Toxicol 2012;8:723-43
   PubMed Web of Science ®Google Scholar
• Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 2006;27:425-46
   PubMed Web of Science ®Google Scholar
• Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006;112:71-105
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Kajosaari LI, Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 2005;77:468-78
   PubMed Web of Science ®Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011;63:157-81
   PubMed Web of Science ®Google Scholar
• Farmer JA. Learning from the cerivastatin experience. Lancet 2001;358:1383-5
   PubMed Web of Science ®Google Scholar
• Fahmi OA, Maurer TS, Kish M, A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 2008;36:1698-708
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K, The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 2006;316:336-48
   PubMed Web of Science ®Google Scholar
• Peters SA, Schroeder PE, Giri N, Dolgos H. Evaluation of the use of static and dynamic models to predict drug-drug interaction and its associated variability: impact on drug discovery and early development. Drug Metab Dispos 2012;40:1495-507
   PubMed Web of Science ®Google Scholar
• Hinton LK, Galetin A, Houston JB. Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. Pharm Res 2008;25:1063-74
   PubMed Web of Science ®Google Scholar
• Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011;51:45-73
   PubMed Web of Science ®Google Scholar
• Yoshida K, Maeda K, Sugiyama Y. Transporter-mediated drug–drug interactions involving OATP substrates: predictions based on in vitro inhibition studies. Clin Pharmacol Ther 2012;91:1053-64
   PubMed Web of Science ®Google Scholar
• Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. Drug Metab Dispos 2011;39:1977-86
   PubMed Web of Science ®Google Scholar
• Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses. Clin Pharmacol Ther 2012;91:846-55
   PubMed Web of Science ®Google Scholar
• USFDA. Drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations. Center for Drug Evaluation and Research (CDER) 2012
   Google Scholar
• EMA. Guideline on the Investigation of Drug Interactions. Committee for Human Medicinal Products (CHMP) 2012
   Google Scholar
• Fahrmayr C, Fromm MF, Konig J. Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects. Drug Metab Rev 2010;42:380-401
   PubMed Web of Science ®Google Scholar
• Fenner KS, Jones HM, Ullah M, The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance. Xenobiotica 2011;42:28-45
   PubMed Web of Science ®Google Scholar
• Niemi M, Schaeffeler E, Lang T, High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004;14:429-40
   PubMedGoogle Scholar
• Lau YY, Huang Y, Frassetto L, Benet LZ. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 2007;81:194-204
   PubMed Web of Science ®Google Scholar
• Regazzi MB, Iacona I, Campana C, Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993;25:2732-4
   PubMed Web of Science ®Google Scholar
• Schneck DW, Birmingham BK, Zalikowski JA, The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004;75:455-63
   PubMed Web of Science ®Google Scholar
• Kock K, Brouwer KL. A perspective on efflux transport proteins in the liver. Clin Pharmacol Ther 2012;92:599-612
   PubMed Web of Science ®Google Scholar
• Klaassen CD, Aleksunes LM. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 2010;62:1-96
   PubMed Web of Science ®Google Scholar
• Di L, Artursson P, Avdeef A, Evidence-based approach to assess passive diffusion and carrier-mediated drug transport. Drug Discov Today 2012;17:905-12
   PubMed Web of Science ®Google Scholar
• Varma MV, Chang G, Lai Y, Physicochemical property space of hepatobiliary transport and computational models for predicting rat biliary excretion. Drug Metab Dispos 2012;40:1527-37
   PubMed Web of Science ®Google Scholar
• Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005;22:11-23
   PubMed Web of Science ®Google Scholar
• Varma MV, Gardner I, Steyn SJ, pH-dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery. Mol Pharm 2012;9:1199-212
   PubMed Web of Science ®Google Scholar
• Sharma P, Butters CJ, Smith V, Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins. Eur J Pharm Sci 2012;47:244-55
   PubMed Web of Science ®Google Scholar
• Soars MG, Barton P, Ismair M, The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery. Drug Metab Dispos 2012;40:1641-8
   PubMed Web of Science ®Google Scholar
• Noe J, Portmann R, Brun ME, Funk C. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 2007;35:1308-14
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 2006;34:1229-36
   PubMed Web of Science ®Google Scholar
• Watanabe T, Maeda K, Kondo T, Prediction of the hepatic and renal clearance of transporter substrates in rats using in vitro uptake experiments. Drug Metab Dispos 2009;37:1471-9
   PubMed Web of Science ®Google Scholar
• Lam JL, Benet LZ. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab Dispos 2004;32:1311-16
   PubMed Web of Science ®Google Scholar
• Li M, Yuan H, Li N, Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human. Eur J Pharm Sci 2008;35:114-26
   PubMed Web of Science ®Google Scholar
• Soars MG, Webborn PJ, Riley RJ. Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry. Mol Pharm 2009;6:1662-77
   PubMed Web of Science ®Google Scholar
• Yabe Y, Galetin A, Houston JB. Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. Drug Metab Dispos 2011;39:1808-14
   PubMed Web of Science ®Google Scholar
• Menochet K, Kenworthy KE, Houston JB, Galetin A. Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes. Drug Metab Dispos 2012;40:1744-56
   PubMed Web of Science ®Google Scholar
• Guguen-Guillouzo C, Guillouzo A. General review on in vitro hepatocyte models and their applications. Methods Mol Biol 2010;640:1-40
   PubMedGoogle Scholar
• Bow DA, Perry JL, Miller DS, Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in freshly isolated rat hepatocytes. Drug Metab Dispos 2008;36:198-202
   PubMed Web of Science ®Google Scholar
• Roelofsen H, Bakker CT, Schoemaker B, Redistribution of canalicular organic anion transport activity in isolated and cultured rat hepatocytes. Hepatology 1995;21:1649-57
   PubMed Web of Science ®Google Scholar
• Kimoto E, Yoshida K, Balogh LM, Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes. Mol Pharm 2012; [Epub ahead of print]
   PubMedGoogle Scholar
• Kimoto E, Chupka J, Xiao Y, Characterization of digoxin uptake in sandwich-cultured human hepatocytes. Drug Metab Dispos 2011;39:47-53
   PubMed Web of Science ®Google Scholar
• Hu Y, Sampson KE, Heyde BR, Saturation of multidrug-resistant protein 2 (mrp2/abcc2)-mediated hepatobiliary secretion: nonlinear pharmacokinetics of a heterocyclic compound in rats after intravenous bolus administration. Drug Metab Dispos 2009;37:841-6
   PubMed Web of Science ®Google Scholar
• Bi YA, Kazolias D, Duignan DB. Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab Dispos 2006;34:1658-65
   PubMed Web of Science ®Google Scholar
• Kotani N, Maeda K, Watanabe T, Culture period-dependent changes in the uptake of transporter substrates in sandwich-cultured rat and human hepatocytes. Drug Metab Dispos 2011;39:1503-10
   PubMed Web of Science ®Google Scholar
• Li N, Singh P, Mandrell KM, Lai Y. Improved extrapolation of hepatobiliary clearance from in vitro sandwich cultured rat hepatocytes through absolute quantification of hepatobiliary transporters. Mol Pharm 2010;7:630-41
   PubMed Web of Science ®Google Scholar
• Bi YA, Kimoto E, Sevidal S, In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation. Drug Metab Dispos 2012;40(6):1085-92
   PubMed Web of Science ®Google Scholar
• Jones HM, Barton HA, Lai Y, Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos 2012;40:1007-17
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kusuhara H, Sugiyama Y. Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans. J Pharmacokinet Pharmacodyn 2010;37:575-90
   PubMed Web of Science ®Google Scholar
• Maeda K, Ikeda Y, Fujita T, Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther 2011;90:575-81
   PubMed Web of Science ®Google Scholar
• Parker AJ, Houston JB. Rate-limiting steps in hepatic drug clearance: comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir. Drug Metab Dispos 2008;36:1375-84
   PubMed Web of Science ®Google Scholar
• Brandt RB, Laux JE, Yates SW. Calculation of inhibitor Ki and inhibitor type from the concentration of inhibitor for 50% inhibition for Michaelis-Menten enzymes. Biochem Med Metab Biol 1987;37:344-9
   PubMedGoogle Scholar
• Ito K, Iwatsubo T, Kanamitsu S, Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 1998;38:461-99
   PubMed Web of Science ®Google Scholar
• Kanamitsu S, Ito K, Sugiyama Y. Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res 2000;17:336-43
   PubMed Web of Science ®Google Scholar
• Rowland M, Matin SB. Kinetics of drug-drug interactions. J Pharmacokinet Pharmacodyn 1973;1:553-67
   Web of Science ®Google Scholar
• Einolf HJ. Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 2007;37:1257-94
   PubMed Web of Science ®Google Scholar
• Goosen TC, Bauman JN, Davis JA, Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos 2007;35:1315-24
   PubMed Web of Science ®Google Scholar
• Obach RS. Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances. Curr Opin Drug Discov Devel 2009;12:81-9
   PubMed Web of Science ®Google Scholar
• Shimizu M, Fuse K, Okudaira K, Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 2005;33:1477-81
   PubMed Web of Science ®Google Scholar
• Kouzuki H, Suzuki H, Ito K, Contribution of sodium taurocholate co-transporting polypeptide to the uptake of its possible substrates into rat hepatocytes. J Pharmacol Exp Ther 1998;286:1043-50
   PubMed Web of Science ®Google Scholar
• Crespi CL, Penman BW. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv Pharmacol 1997;43:171-88
   PubMedGoogle Scholar
• Cui Y, Konig J, Leier I, Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 2001;276:9626-30
   PubMed Web of Science ®Google Scholar
• Ismair MG, Stieger B, Cattori V, Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterology 2001;121:1185-90
   PubMed Web of Science ®Google Scholar
• Schwarz UI, Meyer zu Schwabedissen HE, Tirona RG, Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. Pharmacogenet Genomics 2011;21:103-14
   PubMed Web of Science ®Google Scholar
• Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 2008;36:2014-23
   PubMed Web of Science ®Google Scholar
• Liu L, Pang KS. The roles of transporters and enzymes in hepatic drug processing. Drug Metab Dispos 2005;33:1-9
   PubMed Web of Science ®Google Scholar
• Umehara K, Camenisch G. Novel in vitro-in vivo extrapolation (IVIVE) method to predict hepatic organ clearance in rat. Pharm Res 2012;29:603-17
   PubMed Web of Science ®Google Scholar
• Karlgren M, Ahlin G, Bergstrom CA, In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. Pharm Res 2012;29:411-26
   PubMed Web of Science ®Google Scholar
• Fan J, Chen S, Chow EC, Pang KS. PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. Curr Drug Metab 2010;11:743-61
   PubMed Web of Science ®Google Scholar
• Rostami-Hodjegan A. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther 2012;92:50-61
   PubMed Web of Science ®Google Scholar
• Meyer M, Schneckener S, Ludewig B, Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling. Drug Metab Dispos 2012;40:892-901
   PubMed Web of Science ®Google Scholar
• Poirier A, Cascais AC, Funk C, Lave T. Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn 2009;36:585-611
   PubMed Web of Science ®Google Scholar
• Varma MV, Lai Y, Kimoto E, Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide. Pharm Res 2013, in press
   Web of Science ®Google Scholar
• Watanabe T, Kusuhara H, Maeda K, Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 2009;328:652-62
   PubMed Web of Science ®Google Scholar
• Bolger MB, Lukacova V, Woltosz WS. Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine. AAPS J 2009;11:353-63
   PubMed Web of Science ®Google Scholar
• Varma MV, Lai Y, Feng B, Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharm Res 2012;29:2860-73
   PubMed Web of Science ®Google Scholar
• Korzekwa KR, Nagar S, Tucker J, Models to predict unbound intracellular drug concentrations in the presence of transporters. Drug Metab Dispos 2012;40:865-76
   PubMed Web of Science ®Google Scholar
• Menochet K, Kenworthy KE, Houston JB, Galetin A. Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model. J Pharmacol Exp Ther 2012;341:2-15
   PubMed Web of Science ®Google Scholar
• Kato M, Chiba K, Hisaka A, The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab Pharmacokinet 2003;18:365-72
   PubMedGoogle Scholar
• Guest EJ, Rowland-Yeo K, Rostami-Hodjegan A, Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. Br J Clin Pharmacol 2011;71:72-87
   PubMed Web of Science ®Google Scholar
• Jamei M, Marciniak S, Feng K, The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 2009;5:211-23
   PubMed Web of Science ®Google Scholar
• Zhao P, Vieira Mde L, Grillo JA, Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J Clin Pharmacol 2012;52:91S-108S
   PubMed Web of Science ®Google Scholar
• Damle B, Varma MV, Wood N. Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use. Antimicrob Agents Chemother 2011;55:5172-7
   PubMed Web of Science ®Google Scholar
• Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 2007;6:140-8
   PubMed Web of Science ®Google Scholar
• Kato M, Shitara Y, Sato H, The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Pharm Res 2008;25:1891-901
   PubMed Web of Science ®Google Scholar
• Shimizu K, Takashima T, Yamane T, Whole-body distribution and radiation dosimetry of [(11)C]telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3. Nucl Med Biol 2012;39:847-53
   PubMed Web of Science ®Google Scholar
• Takashima T, Kitamura S, Wada Y, PET imaging-based evaluation of hepatobiliary transport in humans with (15R)-11C-TIC-Me. J Nucl Med 2012;53:741-8
   PubMed Web of Science ®Google Scholar
• Amundsen R, Christensen H, Zabihyan B, Asberg A. Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. Drug Metab Dispos 2010;38:1499-504
   PubMed Web of Science ®Google Scholar
• Park JW, Siekmeier R, Merz M, Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Int J Clin Pharmacol Ther 2002;40:439-50
   PubMed Web of Science ®Google Scholar
• Hedman M, Neuvonen PJ, Neuvonen M, Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther 2004;75:101-9
   PubMed Web of Science ®Google Scholar
• Deng S, Chen XP, Cao D, Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. Clin Ther 2009;31:1256-63
   PubMed Web of Science ®Google Scholar
• Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004;94:1140-6
   PubMed Web of Science ®Google Scholar
• Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003;73:538-44
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63:332-41
   PubMed Web of Science ®Google Scholar
• Mazzu AL, Lasseter KC, Shamblen EC, Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000;68:391-400
   PubMed Web of Science ®Google Scholar
• Becquemont L, Funck-Brentano C, Jaillon P. Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. Fundam Clin Pharmacol 1999;13:232-6
   PubMed Web of Science ®Google Scholar
• Wu LX, Guo CX, Chen WQ, Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment. Br J Clin Pharmacol 2012;73:750-7
   PubMed Web of Science ®Google Scholar
• Simonson SG, Raza A, Martin PD, Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004;76:167-77
   PubMed Web of Science ®Google Scholar
• Busti AJ, Bain AM, Hall RG II, Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol 2008;51:605-10
   PubMed Web of Science ®Google Scholar
• Kiser JJ, Gerber JG, Predhomme JA, Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr 2008;47:570-8
   PubMed Web of Science ®Google Scholar
• van der Lee M, Sankatsing R, Schippers E, Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther 2007;12:1127-32
   PubMed Web of Science ®Google Scholar
• He YJ, Zhang W, Tu JH, Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. Drug Metab Dispos 2008;36:1453-6
   PubMed Web of Science ®Google Scholar
• Allred AJ, Bowen CJ, Park JW, Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers. Br J Clin Pharmacol 2011;72:321-9
   PubMed Web of Science ®Google Scholar
• Samineni D, Desai PB, Sallans L, Fichtenbaum CJ. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. J Clin Pharmacol 2012;52:922-31
   PubMed Web of Science ®Google Scholar
• Pham PA, la Porte CJ, Lee LS, Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother 2009;53:4385-92
   PubMed Web of Science ®Google Scholar